|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEP250 |
Gene summary for CEP250 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEP250 | Gene ID | 11190 |
| Gene name | centrosomal protein 250 | |
| Gene Alias | C-NAP1 | |
| Cytomap | 20q11.22 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q9BV73 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11190 | CEP250 | LZE4T | Human | Esophagus | ESCC | 1.30e-10 | 2.90e-01 | 0.0811 |
| 11190 | CEP250 | LZE5T | Human | Esophagus | ESCC | 1.24e-02 | 5.30e-01 | 0.0514 |
| 11190 | CEP250 | LZE7T | Human | Esophagus | ESCC | 4.87e-08 | 3.91e-01 | 0.0667 |
| 11190 | CEP250 | LZE22T | Human | Esophagus | ESCC | 9.39e-03 | 2.99e-01 | 0.068 |
| 11190 | CEP250 | LZE24T | Human | Esophagus | ESCC | 4.37e-17 | 4.70e-01 | 0.0596 |
| 11190 | CEP250 | P1T-E | Human | Esophagus | ESCC | 4.52e-09 | 5.32e-01 | 0.0875 |
| 11190 | CEP250 | P2T-E | Human | Esophagus | ESCC | 5.42e-14 | 3.57e-01 | 0.1177 |
| 11190 | CEP250 | P4T-E | Human | Esophagus | ESCC | 3.60e-14 | 3.13e-01 | 0.1323 |
| 11190 | CEP250 | P5T-E | Human | Esophagus | ESCC | 1.58e-02 | 1.31e-01 | 0.1327 |
| 11190 | CEP250 | P8T-E | Human | Esophagus | ESCC | 3.93e-08 | 1.96e-01 | 0.0889 |
| 11190 | CEP250 | P9T-E | Human | Esophagus | ESCC | 2.28e-03 | 1.27e-01 | 0.1131 |
| 11190 | CEP250 | P10T-E | Human | Esophagus | ESCC | 1.59e-15 | 3.52e-01 | 0.116 |
| 11190 | CEP250 | P11T-E | Human | Esophagus | ESCC | 1.55e-04 | 2.99e-01 | 0.1426 |
| 11190 | CEP250 | P12T-E | Human | Esophagus | ESCC | 2.15e-21 | 4.39e-01 | 0.1122 |
| 11190 | CEP250 | P15T-E | Human | Esophagus | ESCC | 6.57e-12 | 3.32e-01 | 0.1149 |
| 11190 | CEP250 | P16T-E | Human | Esophagus | ESCC | 2.77e-19 | 3.57e-01 | 0.1153 |
| 11190 | CEP250 | P20T-E | Human | Esophagus | ESCC | 2.86e-08 | 2.71e-01 | 0.1124 |
| 11190 | CEP250 | P21T-E | Human | Esophagus | ESCC | 9.50e-18 | 4.15e-01 | 0.1617 |
| 11190 | CEP250 | P22T-E | Human | Esophagus | ESCC | 6.84e-12 | 2.86e-01 | 0.1236 |
| 11190 | CEP250 | P23T-E | Human | Esophagus | ESCC | 5.28e-13 | 3.02e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:00726985 | Esophagus | ESCC | protein localization to microtubule cytoskeleton | 43/8552 | 54/18723 | 3.28e-07 | 4.61e-06 | 43 |
| GO:00443804 | Esophagus | ESCC | protein localization to cytoskeleton | 45/8552 | 58/18723 | 6.89e-07 | 8.99e-06 | 45 |
| GO:00070982 | Esophagus | ESCC | centrosome cycle | 85/8552 | 130/18723 | 4.41e-06 | 4.69e-05 | 85 |
| GO:00310233 | Esophagus | ESCC | microtubule organizing center organization | 92/8552 | 143/18723 | 5.04e-06 | 5.31e-05 | 92 |
| GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
| GO:19055086 | Esophagus | ESCC | protein localization to microtubule organizing center | 28/8552 | 35/18723 | 3.40e-05 | 2.78e-04 | 28 |
| GO:00715396 | Esophagus | ESCC | protein localization to centrosome | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
| GO:0010457 | Esophagus | ESCC | centriole-centriole cohesion | 12/8552 | 14/18723 | 2.51e-03 | 1.08e-02 | 12 |
| GO:19055153 | Esophagus | ESCC | non-motile cilium assembly | 39/8552 | 61/18723 | 3.08e-03 | 1.28e-02 | 39 |
| GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
| GO:0031023 | Liver | HCC | microtubule organizing center organization | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
| GO:0007098 | Liver | HCC | centrosome cycle | 75/7958 | 130/18723 | 3.33e-04 | 2.34e-03 | 75 |
| GO:00443802 | Liver | HCC | protein localization to cytoskeleton | 38/7958 | 58/18723 | 3.37e-04 | 2.36e-03 | 38 |
| GO:007269811 | Liver | HCC | protein localization to microtubule cytoskeleton | 35/7958 | 54/18723 | 7.73e-04 | 4.65e-03 | 35 |
| GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
| GO:190550811 | Liver | HCC | protein localization to microtubule organizing center | 23/7958 | 35/18723 | 4.72e-03 | 2.02e-02 | 23 |
| GO:007153911 | Liver | HCC | protein localization to centrosome | 21/7958 | 33/18723 | 1.16e-02 | 4.28e-02 | 21 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEP250 | SNV | Missense_Mutation | c.3691N>A | p.Pro1231Thr | p.P1231T | Q9BV73 | protein_coding | tolerated(0.23) | benign(0.073) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CEP250 | SNV | Missense_Mutation | c.1636N>G | p.Arg546Gly | p.R546G | Q9BV73 | protein_coding | deleterious(0.01) | benign(0.188) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| CEP250 | SNV | Missense_Mutation | novel | c.1045A>C | p.Thr349Pro | p.T349P | Q9BV73 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| CEP250 | SNV | Missense_Mutation | c.4303G>C | p.Glu1435Gln | p.E1435Q | Q9BV73 | protein_coding | tolerated(0.2) | benign(0.045) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CEP250 | SNV | Missense_Mutation | rs542508593 | c.6479N>C | p.Arg2160Thr | p.R2160T | Q9BV73 | protein_coding | deleterious(0) | possibly_damaging(0.647) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
| CEP250 | SNV | Missense_Mutation | rs759294916 | c.6449N>A | p.Arg2150Gln | p.R2150Q | Q9BV73 | protein_coding | tolerated(0.93) | benign(0.001) | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CEP250 | SNV | Missense_Mutation | c.3067G>A | p.Asp1023Asn | p.D1023N | Q9BV73 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CEP250 | SNV | Missense_Mutation | c.416A>G | p.Glu139Gly | p.E139G | Q9BV73 | protein_coding | tolerated(1) | benign(0.01) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CEP250 | SNV | Missense_Mutation | novel | c.6974N>C | p.Ile2325Thr | p.I2325T | Q9BV73 | protein_coding | tolerated(0.36) | benign(0.001) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CEP250 | SNV | Missense_Mutation | rs377120249 | c.3517G>A | p.Gly1173Arg | p.G1173R | Q9BV73 | protein_coding | deleterious(0.01) | benign(0.035) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |